Fideuram - Intesa Sanpaolo Private Banking’s Apellis Pharmaceuticals APLS Stock Holding History

Fideuram - Intesa Sanpaolo Private Banking’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4	Closed	-$161	–	450
2026 Q1	$161	Hold	4	–	–	﹤0.01%	455
2025 Q4	$100	Buy	+4	New	+$94	﹤0.01%	434

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fideuram - Intesa Sanpaolo Private Banking's APLS Position: Q2 2026 in Review

Fideuram - Intesa Sanpaolo Private Banking sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 4 shares — an estimated $161 sold.

Fideuram - Intesa Sanpaolo Private Banking first reported a position in APLS in Q4 2025 and held it in 2 quarters. The position peaked at $161 in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Fideuram - Intesa Sanpaolo Private Banking reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Fideuram - Intesa Sanpaolo Private Banking sold 4 Apellis Pharmaceuticals shares in Q2 2026, an estimated $161.
Fideuram - Intesa Sanpaolo Private Banking first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Fideuram - Intesa Sanpaolo Private Banking's Apellis Pharmaceuticals position peaked at $161 in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Fideuram - Intesa Sanpaolo Private Banking's 13F filing for Q2 2026, filed 23 Jul 2026.